Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

GenVec, Inc. (NASDAQ: GNVC) GenVec, Inc. is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec’s development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD).

Cenix BioScience is a contract research organization specialized in combining advanced applications of RNAi with high content phenotypic analyses to enhance and accelerate the discovery and pre-clinical development of novel therapeutics. Cenix has built up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields. The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs. As such, Cenix is a mature and fully-proven industrial research provider, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none world wide

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Part of Dyadic International, Inc., Dyadic International (USA), Inc. is a company headquartered in Jupiter, FL, involved in biological products, except diagnostic substances. Mark A. Emalfarb is the current CEO of the firm.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Institut de Recherche pour le Développement operates as a scientific and technical public institution which provides information, expertise, support and training in production performance. It performs research centered on the relationship between human beings and its environment in intertropical areas. In that context the IRD implements research projects on sleeping sickness and the vectors transmitting the disease. The company is headquartered in Marseille, France.

Activate Immunotherapy operates as a clinical-stage biopharmaceutical company. The firm discovers, develops, and commercializes Immunotherapies for the treatment of cancer. The company was founded by Habib Fakhrai and Emmet O’Neal III in 1997 and is headquartered in San Diego, CA.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Zhuhai Shutong Medical Technology Co., Ltd., established on 2019-12-31, Business scope includes general items:Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Biochemical product technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;R&D and application of cell technology;Research and development of bio-based material polymerization technology;Development of Human Gene Diagnosis and Therapy Technology;Technology intermediary service;Information Consulting Service(Not including licensing information consulting services);Research and development of biopesticide technology;Import and export;Technology Import and Export;Internet of things technology research and development;Internet of Things Technology Services;internet sales(Except for products that require a license for sale).(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

Merck Serono S.A. discovers, develops, manufactures, and commercializes prescription medicines focusing on various therapeutic areas that include oncology, immuno-oncology, immunology, multiple sclerosis, fertility, endocrinology, biosimilars, and neglected diseases. It develop treatments to help manage neurodegenerative diseases, such as multiple sclerosis; colorectal cancer; drugs to treat head and neck cancer; fertility drugs for every stage of the reproductive cycle.

Danisco US, Inc. manufactures synthetic resins, synthetic rubbers and industrial chemicals. The company is headquartered in Wilmington, DE.